

Andreas HUTH et al.

Examiner: Unassigned

Serial No.: 10/631,018

Group Art Unit: Unassigned

Filed: July 31, 2003

For VEGFR-2 AND VEGFR-3 INHIBITORY ANTHRANILAMIDE PYRIDINAMIDES

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

According to the formal Filing Receipt (copy attached), please make the corrections listed below:

The current filing receipt claims only benefit of German Application No. 10235690.4 of July 31, 2002. However, in the submission of priority documents of November 14, 2003, the benefit of German Priority 10328036.7 of June 19, 2003 was also claimed. This should be added to the filing receipt.

As well, in the concurrently filed preliminary amendment, benefit is being claimed of U.S. Provisional Application No. 60/407,970 filed on September 5, 2002 and U.S. Provisional Application No. 60/483,896 filed on July 2, 2003. The filing receipt should also be updated in this regard.

REMARKS

A copy of our Submission of Priority Documents is attached. It is believed that no fee is required since these are PTO errors. Accordingly, Applicants courteously request a corrected filing receipt.

Respectfully submitted,

Anthony J. Zalano, Reg. No. 27,969

Attorney for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703)243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1922

Date: August 18, 2004 K:\Sch\1922\ReqCorrectedFR.doc



United States Patent and Trademark Office



United States Potent and Trademark Office Address COMMISSIONER 1908, PRESENTE & Branigan P.C. P.O. Sox 1450, Alexandria, Virginia 22313-1450

FILING OR 371 (c) DATE FIL FEE REC'D ATTY.DOCKET NO **DRAWINGS TOT CLMS** IND CLMS ART UNIT APPL NO. 11

10/631,018 07/31/2003 1645

1030

SCH-1922

23599 MILLEN, WHITE, ZELANO & BRANIGAN, P. 2200 CLARENDON BLVD. **SUITE 1400** ARLINGTON, VA 22201



CONFIRMATION NO. 9530 UPDATED FILING RECEIPT OC000000012323979*

Date Mailed: 04/09/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andreas Huth, Berlin, GERMANY; Ludwig Zorn, Berlin, GERMANY; Martin Kruger, Berlin, GERMANY; Stuart Ince, Berlin, GERMANY; Karl-Heinz Thierauch, Berlin, GERMANY; Andreas Menrad, Berlin, GERMANY; Martin Haberey, Berlin, GERMANY; Holger Hess-Stumpp, Berlin, GERMANY;

Domestic Priority data as claimed by applicant

Foreign Applications

GERMANY 10235690.4 07/31/2002

If Required, Foreign Filing License Granted: 12/02/2003

Projected Publication Date: 07/22/2004

Non-Publication Request: No

Early Publication Request: No

Title

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).